{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:32:34Z","timestamp":1767339154629,"version":"3.43.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2017R1A1A3A04069864"],"award-info":[{"award-number":["NRF-2017R1A1A3A04069864"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.arcmed.2024.103158","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:25:45Z","timestamp":1736155545000},"page":"103158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mutational Profiling of Korean Lymphomas and Diffuse Large B-Cell Lymphoma Subtype Classification Using Targeted Panel Sequencing"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6919-0019","authenticated-orcid":false,"given":"Gilsung","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jooyoung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeong Ju","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taesic","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-1848","authenticated-orcid":false,"given":"JinJu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2024.103158_bib0001","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.pop.2016.07.012","article-title":"Lymphoma","volume":"43","author":"Mugnaini","year":"2016","journal-title":"Prim Care"},{"key":"10.1016\/j.arcmed.2024.103158_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arcmed.2024.103158_bib0003","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and etiology of leukemia and lymphoma","volume":"10","author":"Bispo","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.arcmed.2024.103158_bib0004","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2024.103158_bib0005","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jmoldx.2017.11.010","article-title":"Assessment of capture and amplicon-based approaches for the development of a targeted next-generation sequencing pipeline to personalize lymphoma management","volume":"20","author":"Hung","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.arcmed.2024.103158_bib0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.csbj.2019.11.002","article-title":"Long walk to genomics: history and current approaches to genome sequencing and assembly","volume":"18","author":"Giani","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.arcmed.2024.103158_bib0008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.arcmed.2024.103158_bib0009","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2024.103158_bib0010","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2024.103158_bib0011","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0012","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2024.103158_bib0013","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.arcmed.2024.103158_bib0014","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/s41598-019-52000-3","article-title":"Development and validation of a targeted gene sequencing panel for application to disparate cancers","volume":"9","author":"McCabe","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2024.103158_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.7150\/jca.27615","article-title":"Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA","volume":"10","author":"Sun","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.arcmed.2024.103158_bib0016","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fonc.2020.00898","article-title":"Genomics of peripheral T-cell lymphoma and its implications for personalized medicine","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0017","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4143\/crt.2017.093","article-title":"Nationwide statistical analysis of lymphoid malignancies in Korea","volume":"50","author":"Lee","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.arcmed.2024.103158_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-13150-4_1","article-title":"Epidemiology and etiology of non-hodgkin lymphoma","volume":"165","author":"Chiu","year":"2015","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.arcmed.2024.103158_bib0019","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0020","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.18632\/oncotarget.14008","article-title":"Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies","volume":"8","author":"Cani","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2024.103158_bib0021","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3390\/ijms17050683","article-title":"Gene mutation profiles in primary diffuse large B cell lymphoma of central nervous system: next generation sequencing analyses","volume":"17","author":"Todorovic Balint","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2024.103158_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5808\/GI.2016.14.3.78","article-title":"Mutational analysis of extranodal NK\/T-Cell lymphoma using targeted sequencing with a Comprehensive Cancer Panel","volume":"14","author":"Choi","year":"2016","journal-title":"Genomics Inform"},{"key":"10.1016\/j.arcmed.2024.103158_bib0023","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0024","first-page":"51","article-title":"Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy","volume":"18","author":"Jardin","year":"2014","journal-title":"Discov Med"},{"key":"10.1016\/j.arcmed.2024.103158_bib0025","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00277-014-2116-y","article-title":"Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy","volume":"93","author":"Carbone","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0026","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.arcmed.2024.103158_bib0027","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.arcmed.2024.103158_bib0028","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.17765","article-title":"Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort","volume":"195","author":"Mishina","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0029","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.semcancer.2013.04.002","article-title":"Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies","volume":"23","author":"Rossi","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0030","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2015.134510","article-title":"Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond","volume":"101","author":"Rosenquist","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.arcmed.2024.103158_bib0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.arcmed.2024.103158_bib0032","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12308-019-00369-5","article-title":"Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study","volume":"12","author":"Jung","year":"2019","journal-title":"J Hematop"},{"key":"10.1016\/j.arcmed.2024.103158_bib0033","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4143\/crt.2017.093","article-title":"Nationwide statistical analysis of lymphoid malignancies in Korea","volume":"50","author":"Lee","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.arcmed.2024.103158_bib0034","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41379-020-00720-7","article-title":"Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice","volume":"34","author":"Davis","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0035","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0036","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1541-7786.MCR-20-0466","article-title":"Aggressive B-cell lymphoma with MYC\/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents","volume":"19","author":"Deng","year":"2021","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.arcmed.2024.103158_bib0037","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-Cell lymphoma treated with CD19-chimeric antigen receptor T-Cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0038","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2024.103158_bib0039","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","author":"Kraan","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.arcmed.2024.103158_bib0040","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.3390\/cancers12102913","article-title":"Oncogenic mutations of MYD88 and CD79B in diffuse large B-Cell lymphoma and implications for clinical practice","volume":"12","author":"Visco","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.arcmed.2024.103158_bib0041","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-Cell lymphoma: analysis of 361 cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2024.103158_bib0042","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12935-020-01518-y","article-title":"Ibrutinib in B-cell lymphoma: single fighter might be enough?","volume":"20","author":"Xue","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.arcmed.2024.103158_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211072839","article-title":"MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy","volume":"13","author":"Chen","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0044","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.humpath.2013.10.023","article-title":"CD79B and MYD88 mutations in diffuse large B-cell lymphoma","volume":"45","author":"Kim","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0045","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2024.103158_bib0046","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2024.103158_bib0047","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.arcmed.2024.103158_bib0048","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2013-01-479865","article-title":"Analysis of FOXO1 mutations in diffuse large B-cell lymphoma","volume":"121","author":"Trinh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0049","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423183","article-title":"FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy","volume":"7","author":"Pyrzynska","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.arcmed.2024.103158_bib0050","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic landscapes of relapsed and refractory diffuse large B-Cell lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2024.103158_bib0051","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fonc.2018.00550","article-title":"The NOTCH pathway and its mutations in mature B cell malignancies","volume":"8","author":"Arruga","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0052","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17132","article-title":"Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL)","volume":"192","author":"Runge","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100007","article-title":"Genetic profiling in diffuse large B-cell lymphoma: the promise and the challenge","volume":"36","author":"Cutmore","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0054","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2024.103158_bib0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/leu.2011.266","article-title":"High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis","volume":"26","author":"Launay","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2024.103158_bib0056","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2024.103158_bib0057","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.arcmed.2024.103158_bib0058","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2015-10-679191","article-title":"TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses","volume":"128","author":"Kotsiou","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0059","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.arcmed.2024.103158_bib0060","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"year":"2017","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","key":"10.1016\/j.arcmed.2024.103158_bib0061"},{"key":"10.1016\/j.arcmed.2024.103158_bib0062","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2024.103158_bib0063","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0064","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.arcmed.2024.103158_bib0065","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.critrevonc.2012.06.004","article-title":"Anaplastic large cell lymphoma, ALK-negative","volume":"85","author":"Ferreri","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0066","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0067","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100007","article-title":"Genetic profiling in diffuse large B-cell lymphoma: the promise and the challenge","volume":"36","author":"Cutmore","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0069","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11864-020-0720-8","article-title":"Immunomodulators in lymphoma","volume":"21","author":"Anagnostou","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.arcmed.2024.103158_bib0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/asheducation-2017.1.310","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"2017","author":"Liu","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.arcmed.2024.103158_bib0071","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.arcmed.2024.103158_bib0072","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/bloodadvances.2021006845","article-title":"Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL","volume":"7","author":"Shi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.arcmed.2024.103158_bib0073","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-024-47198-4","article-title":"Combination of acalabrutinib with lenalidomide and rituximab in relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial","volume":"15","author":"Park","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.arcmed.2024.103158_bib0074","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.gim.2022.07.001","article-title":"Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)","volume":"24","author":"Horak","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.arcmed.2024.103158_bib0075","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood-2018-01-827881","article-title":"Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes","volume":"131","author":"Padron","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2024.103158_bib0076","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1373\/clinchem.2014.223040","article-title":"Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization","volume":"61","author":"Do","year":"2015","journal-title":"Clin Chem"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440924002091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440924002091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T08:51:36Z","timestamp":1754902296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440924002091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0188440924002091"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2024.103158","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutational Profiling of Korean Lymphomas and Diffuse Large B-Cell Lymphoma Subtype Classification Using Targeted Panel Sequencing","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2024.103158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103158"}}